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INTRODUCTION
Atherosclerosis and coronary artery disease (CAD), which
is developed as a complication of atherosclerosis, are one of
the major causes of death in the world (1). Traditional risk
factors of coronary artery disease are hypertension, diabetes
mellitus, dyslipidemia, and smoking. However, these fac-
tors can only explain approximately two thirds of the observ-
ed clinical events. This has maintained interest in other nutri-
tional, biochemical, and genetic factors that might contribute
to the underlying pathophysiology of vascular disease (2).
Cancers as well as CAD are also the main causes of death
in developed countries. They share common disease origin
and pathogenetic mechanisms (3). Recent studies address-
ing the issue of somatically acquired DNA mutations in the
pathogenesis of atherosclerosis suggest that the occurrence
of DNA alterations contribute to the multifaceted patho-
genesis of the atherogenic process. In particular, deletions or
mutations of gene coding for enzymes involved in the meta-
bolism of hazardous compounds may be responsible for indi-
vidual susceptibility to genotoxic factors, predisposing to the
development of DNA insults (4, 5). Also twin and nuclear
family studies provide compelling evidence of a genetic com-
ponent underlying cardiovascular disease (6).
The glutathione S-transferases (GST) are a family of enzymes
that detoxify reactive electrophiles, particularly in tobacco
smoke, products of oxidative stress, and known or suspected
carcinogenic compounds such as benzo[a]pyrene and other
polycyclic aromatic hydrocarbons (7). There are four classes of
GST isoenzymes in humans ( ,  ,  , and ), with partially
overlapping substrate specificities (8). GST M1 enzyme belongs
to the  class and the GSTT1 enzyme to the  class. The
GSTM1 gene on chromosome 1p13, according to the three
alleles, can be grouped into two classes: GSTM1-null homozy-
gote for the null allele (GSTM1-0), nonfunctional class and
GSTM1-1 with at least one of the GSTM1a or GSTM1b
alleles, functional class (9). GSTM1-null was reported to be
associated in some studies with increased susceptibility to
inflammatory pathologies and increased risk of smoking-
related cancers (10, 11). 
Similarly, GSTT1 gene on chromosome 22q11,2 has two
classes denoted as GSTT1-null homozygote for the null
allele (GSTT1-0), and GSTT1-1 with at least one function-
al allele. The GSTT1 enzyme encoded by GSTT1-1 catalyzes
the detoxification of monohalomethanes and ethylene oxide,
present in cigarette smoke (12), and deficiency of its activity
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Impact of Glutathione S-Transferase M1 and T1 Gene Polymorphisms
on the Smoking-Related Coronary Artery Disease
Glutathione S-transferase (GST) plays a key role in the detoxification of xenobiotic
atherogen generated by smoking. To analyze the effect of GSTM1/T1 gene poly-
morphisms on the development of smoking-related coronary artery disease (CAD),
775 Korean patients who underwent coronary angiography were enrolled. The sub-
jects were classified by luminal diameter stenosis into group A (>50%), B (20-50%),
or C (<20%). GSTM1 and GSTT1 gene polymorphisms were analyzed using mul-
tiplex polymerase chain reaction (PCR) for GSTM1/T1 genes and CYP1A1 gene
for internal control. Of 775 subjects, 403 patients belonged to group A. They had
higher risk factors for CAD than group B (N=260) and group C (N=112). The geno-
type frequencies of null GSTM1 and GSTT1 showed no significant differences
among 3 groups. Considering the effect of GSTM1 gene polymorphisms on the
smoking-related CAD, smokers with GSTM1 null genotype had more increased
risk for CAD than non-smoker with GSTM1 positive genotype (odds ratios [OR],
2.07, confidence interval [CI], 1.06-4.07). Also the effect of GSTT1 gene polymor-
phism on smoking-related CAD showed the same tendency as GSTM1 gene (OR,
2.00, CI, 1.05-3.84). This effect of GSTM1/T1 null genotype on smoking-related
CAD was augmented when both gene polymorphisms were considered simulta-
neously (OR, 2.76, CI, 1.17-6.52). We concluded that GSTM1/T1 null genotype
contributed to the pathogenesis of smoking-related CAD to some degree.
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Tobacco smoke is a major cause of both cancer and cardio-
vascular diseases. Although its carcinogenic role via induc-
tion of DNA damage and mutation is well established, the
mechanisms involved in vascular disease remain unclear. One
possible cause is that DNA damage causes smooth muscle
cell proliferation in the intima of arteries, thereby contribut-
ing to atherothrombotic processes. The binding of chemi-
cals to DNA is modulated by detoxification enzymes (14).
Mutagenic and mitogenic activity of cigarette smoke chem-
icals can cause DNA adducts in target tissues and the oxida-
tive modification of lipoproteins (15), endothelial cell regen-
eration (16), and progression of atherosclerotic lesions (15).
Epidemiological studies have indicated that GSTM1 and
GSTT1 polymorphisms are associated with increased risk
for different cancers among smokers, but there are still some
controversies about the relationship between GST polymor-
phism and CAD in smokers (7, 17).
The GST enzyme is implicated in the detoxification of
carcinogens present in tobacco smoke and consequently poly-
morphisms in this gene may confer susceptibility to cardio-
vascular disease if DNA damage is important in the develop-
ment of CAD. So the aims of this study are to assess whether
the GSTM1 and GSTT1 genotypes are associated with CAD,
and to ascertain whether the risk of CAD given exposure to
cigarette smoking is modified by the specific genetic poly-
morphisms of GSTM1 and GSTT1.
MATERIALS AND METHODS
Subjects 
The study population consisted of 775 patients who had
undergone coronary angiography from June 2004 to March
2005 in Kyunghee University Hospital. Most of them (703
of 775) had received the coronary angiography for confirma-
tive diagnosis and treatment of ischemic heart disease with
typical chest pain, and 72 subjects for preoperative evalua-
tion of valvular heart disease or other reasons. We classified
the subjects into 3 groups according to the degree of lumi-
nal diameter stenosis in coronary angiography: group A rep-
resents subjects with more than 50% of luminal diameter
stenosis, group B with luminal diameter stenosis between
20% and 50%, and group C with less than 20%. Smoking
history, hypertension, diabetes mellitus, family histoy of car-
diovascular disease, and obesity were evaluated by history tak-
ing and physical examination. Smoker was defined as both
current smoker and ex-smoker who had previously been ex-
posed to smoking for at least 5 yr. Hypertension was defined
as patients who had been previously diagnosed and received
anti-hypertensive drugs, or patients whose blood pressure
level was more than 140 mmHg in systole or more than 90
mmHg in diastole. Diabetes mellitus was defined as patients
who had been previously diagnosed and received oral hypo-
glycemic agents or insulin therapy, or patients whose fast-
ing blood glucose (FBS) was above 126 mg/dL or postpran-
dial 2 hour blood glucose (PP2hr glucose) above 200 mg/dL.
Dyslipidemia was defined as patients who had taken statin
treatment with diagnosis of hyperlipidemia or patients whose
low-density lipoprotein cholesterol (LDL) level was above
160 mg/dL or high-density lipoprotein cholesterol (HDL)
level below 40 mg/dL. Body mass index (BMI, kg/m2) was
calculated using the height and weight. Informed consent
was obtained from all subjects, and the study was approved
by the Ethical Committee of Kyunghee University.
Methods 
Blood test
We determined the baseline blood test including the FBS,
PP2hr glucose and lipid profile such as total cholesterol,
triglyceride, LDL and HDL. 
Coronary angiography
Coronary angiography was carried out according to the
Judkins techinique, and images of the right and left coronary
trees were obtained in routine standardized projections with
Philips Integris Allura 9 system (Philips Medical, Eindhoven,
Netherlands). Quantitative coronary angiography was exe-
cuted by experienced angiographers who were blind to the
results of genotype analysis. CAD was defined as luminal
diameter narrowing more than 50% in at least one epicardial
coronary artery. The severity of CAD was determined by the
number of affected vessels in coronary arteris (one-, two-, or
three-vessel disease). Also we devided the CAD according
to the degree of luminal narrowing into mild (50-75%),
moderate (75-90%), and severe (more than 90%).
Genetic assessment
Blood samples and DNA isolation Venous blood of 3 mL
was obtained from all subjects and collected in sterile tubes
containing ethylenediaminetetraacetic acid (EDTA). Immedi-
ately after collection, whole blood was stored at -20℃ until
use. Genomic DNA was extracted from whole blood by using
Whole Blood Genomic DNA Purification (Rapid Spin Type,
CoreBio, Indianapolis, IN, U.S.A.)
Analysis of GSTM1 and GSTT1 gene polymorphisms The
genetic polymorphism analyses for the GSTM1 and GSTT1
gene were determined by the multiplex polymerase chain
reaction (PCR) modifying the previously described method
(18). The appropriate fragment of the GST gene for GSTM1
and GSTT1 was amplified with specific primers from human
genomic DNA. The CYP1A1 gene was coamplified as an
internal positive control. The following primers were used
in PCR reaction: GSTM1 primers of (sense) 5-GAACTC-
CCTGAAAAGCTAAAGC-3 and (antisense) 5-GTTGG-
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5-TTCCTTACTGGTCCTCACATCTC-3 and (antisense)
5-TCACGGGATCATGGCCAGCA-3, and CYP1A1 (sense)
5-GAACTGCCACTTCAGCTGTCT-3 and (antisense) 5-
CAGCTGCATTTGGAAGTGCTC-3.
PCR was performed in a total volume of 30  L reaction mix
containing 100 μ g genomic DNA, 5  M of each primer,
2.5 mM deoxyribonucleoside triphosphates, 1.5 mM MgCl2,
100 mM Tris-HCL, and 1 U thermostable Taq DNA poly-
merase with GeneAmp PCR system 2700 (Applied Biosys-
tems, Foster, CA, U.S.A.). The amplification conditions were
initial denaturation at 94℃for 5 min followed by 35 cycles
of denaturation at 94℃ for 45 sec, annealing at 59℃ for
50 sec, extension at 72℃ for 1 min, and final extension at
72℃ for 10 min. The products of the PCR amplification
(GSTM1:215 bp, GSTT1:480 bp, CYP1A1:312 bp) were
separated then electrophoretically on an ethidium bromide-
stained 2% agarose gel.
Statistical analysis 
Statistical analysis of data was conducted with SPSS 12.0
program. Data of continuous variables were expressed as mean
±standard deviation and data of noncontinuous variables as
frequency (N, %). Differences of means among group A, B,
and C were evaluated by one-way analysis of variance (AN-
OVA). Comparison of noncontinuous variables and genotype
distribution among 3 groups were tested by using  2 test (2×
2 continency table). We calculated odds ratios (OR) and 95%
confidence interval (CI) for the association of the GSTM1
and GSTT1 genotypes with the development of CAD using
unconditional logistic regression. The OR was also adjusted
for other coronary risk factors. Independent factors on CAD
risk were evaluated by multiple logistic regression model. p
values of <0.05 were considered statistically significant.
RESULTS
Clinical characteristics
The clinical characteristics for 775 subjects are shown in
Table 1. Of 775 subjects, 403 subjects belonged to group A,
260 to group B, and 112 to group C. The prevalence of known
atherogenic risk factors, such as smoking habits, hyperten-
sion, diabetes, dyslipidemia, obesity, and sex (male) were
significantly higher in group A as compared with group B
and C. We found that the HDL level was significantly lower
in group A than in group B and C (36.0±12.0 in group A
vs. 40.5±11.3 in group B, and vs. 40.2±10.5 mg/dL in
group C, respectively, p<0.05). Average smoking history was
30.2 pack years. There was no difference in smoking habits
between group A and B, but there was significant difference
between group A and C (31.4 pack years in group A vs. 26.8
pack years in group C, p<0.05). There was no significant dif-
ference in clinical characteristics between group B and C.
GSTM1/T1 gene polymorphism
The internal standard fragment amplified from GSTM1
gene was 215 bp. A 480-bp fragment was amplified for the
GSTT1 gene, and 312-bp fragment was obtained for CYP1A1
gene. The absence of other amplified products with only
presence of 312-bp fragment was consistent with the null
genotypes (Fig. 1). 
We acquired data for GSTM1 gene and GSTT1 gene poly-
morphisms in 692 subjects (89.3%) due to missing data of
gene analysis (missing data [83]: group A [47], B [34], and
C [2]).
The relation of GSTM1/T1 gene polymorphism to coro-
nary artery disease
There was no significant difference in GSTM1 and GSTT1
genotype distribution among 3 groups (Table 2). We found
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*, p<0.001 vs. group B and group C; 
� , p<0.05 vs. group C; 
� , p<0.05
vs. group B and group C.
Group A, ≥50% in luminal diameter stenosis in coronary angiography;
Group B, 20-50% in luminal diameter stenosis in coronary angiography;
Group C, <20% in luminal diameter stenosis in coronary angiography.
BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-









Age (yr) 63.3±10.4* 57.4±11.4 58.1±12.6 <0.001
Male (%) 63.4* 48.3 47.3 <0.001
Smoking (%) 47.5* 31.0 29.5 <0.001
Pack-years 31.4
� 31.0 26.8 <0.05
BMI (kg/m
2) 25.2±4.1
� 23.4±3.6 22.8±3.1 <0.05
Diabetes (%) 34.0* 19.3 14.3 <0.001
Hypertension (%) 61.8* 48.3 48.2 <0.001
Dyslipidemia (%) 69.3* 51.9 50.9 <0.001
Cholesterol 183.4±38.8 180.4±42.4 178.1±33.7 NS
(mg/dL)
Triglyceride 145.5±91.2 131.5±85.1 144.8±105.9 NS
(mg/dL)
HDL-C (mg/dL) 36.0±12.0* 40.5±11.2 40.2±10.5 <0.005
LDL-C (mg/dL) 118.2±32.7 110.3±30.9 108.5±25.2 NS
Table 1. Demographic characteristics of subjects






CYP1A1no difference in genotype distribution among 3 groups when
we classified subjects into smokers and non-smokers. When
the risks associated with GST genotypes for CAD were con-
sidered in relation to smoking habits, smokers with GSTM1
null genotype were at an approximately 2.07-fold higher risk
of CAD than nonsmokers with GSTM1-positive genotype
(CI, 1.06-4.07, p=0.03). However, smokers with GSTM1-
positive genotype had no increased risk for CAD as compar-
ed with non-smokers (OR, 1.21, CI, 0.64-2.27). In non-
smokers, there was no difference in CAD risk according to
GSTM1 genotype (OR, 0.96, CI, 0.56-1.66). There was no
effect of interaction of GSTM1 genotype and smoking on
CAD development between group B and C (Table 3). 
The effect of interaction of GSTT1 gene and smoking on
CAD risk, we found the similar results as those in GSTM1
gene. Smokers with GSTT1 null genotype were at an approx-
imately 2.0-fold higher risk of CAD than nonsmokers with
GSTT1 positive genotype (CI, 1.05-3.84, p=0.03). Howev-
er, smokers with GSTT1-positive genotype had no increased
risk for CAD as compared with non-smokers (OR, 1.44, CI,
0.74-2.84). In non-smokers, there was no difference in CAD
risk in relation to GSTT1 genotype (OR, 0.77, CI, 0.45-
1.31). There was no effect of interaction of GSTT1 genotype
and smoking on CAD development between group B and C
(Table 4). 
Considering the synergistic effects of GSTM1 null geno-
type and GSTT1 null genotype on risk of smoking-related
CAD, we found that smokers with both GSTM1 and GSTT1
null genotype were at an approximately 2.76-fold higher risk
of CAD than nonsmokers with both GSTM1 and GSTT1
positive genotype (CI, 1.17-6.52, p=0.04) 
After adjusting other coronary risk factors such as hyper-
tension, diabetes, dyslipidemia, age, and sex than smoking,
the interactive effect GSTM1/GSTT1 gene and smoking on
CAD remained statistically significant (in smokers with
GSTM1 null genotype, OR, 2.01, CI, 1.13-3.69, p=0.01/in
smokers with GSTT1 null genotype, OR, 1.89, CI, 1.03-
3.13, p=0.02) (Table 5, 6).
As we considered the effect of GSTM1/GSTT1 genotype
on the multivessel disease, there was no significant difference
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*, Valid results of GSTM1/GSTT1 genotype were 692 of 775 subjects
(89.3%).
Group A, ≥50% in luminal diameter stenosis in coronary angiography;
Group B, 20-50% in luminal diameter stenosis in coronary angiography;
Group C, <20% in luminal diameter stenosis in coronary angiography.











Null 198 (55.61) 134 (59.3) 57 (51.8) 1.88 (0.39)
Positive 158 (44.39) 92 (40.7) 53 (48.2)
GSTT1 (n=692)
Null 196 (55.06) 126 (55.8) 61 (55.4) 0.03 (0.98)
Positve 160 (44.94) 100 (44.2) 49 (46.6)









Group A vs. C
OR (95% CI)
Group B vs. C
M1(+)/NS* 85 (46.2) 67 (36.8) 31 (17.0)
M1(-)/NS 108 (44.2) 94 (38.8) 41 (17.0) 0.02 (0.89) 0.96 (0.56-1.66) 1.06 (0.60-1.86)
M1(+)/S 73 (60.8) 25 (20.8) 22 (18.4) 0.51 (0.47) 1.21 (0.64-2.27) 0.53 (0.26-1.07)
M1(-)/S 90 (61.6) 40 (27.4) 16 (11.0) 4.64 (0.03) 2.07 (1.06-4.07) 1.16 (0.56-2.37)
Table 3. Interaction between GSTM1 genotype and smoking on CAD
*, reference.
Group A, ≥50% in luminal diameter stenosis in coronary angiography; Group B, 20-50% in luminal diameter stenosis in coronary angiography; Group
C, <20% in luminal diameter stenosis in coronary angiography.










Group A vs. C
OR (95% CI)
Group B vs. C
T1(+)/NS* 94 (46.1) 77 (37.8) 33 (16.1)
T1(-)/NS 97 (43.8) 79 (36.1) 44 (20.1) 0.96 (0.33) 0.77 (0.45-1.31) 0.77 (0.44-1.33)
T1(+)/S 67 (62.9) 24 (21.9) 16 (15.2) 1.16 (0.28) 1.44 (0.74-2.84) 0.62 (0.29-1.31)
T1(-)/S 98 (60.6) 46 (28.8) 17 (10.6) 4.48 (0.03) 2.00 (1.05-3.84) 1.16 (0.58-2.31)
Table 4. Interaction between GSTT1 genotype and smoking on CAD
*, reference.
Group A, ≥50% in luminal diameter stenosis in coronary angiography; Group B, 20-50% in luminal diameter stenosis in coronary angiography; Group
C, <20% in luminal diameter stenosis in coronary angiography.
GST, glutathione S-transferase; CAD, coronary artery disease; OR, odds ratio; T1(+), GSTT1-positive genotype; T1(-), GSTT1 null genotype; NS, non-
smoker; S, smoker.in GSTM1/GSTT1 genotype in relation to the number of
involved vessel in both smokers and non-smokers (Table 7).
Also, there was no significant effect of GSTM1/GSTT1 geno-
type on the severity of CAD (Table 8).
We examined independent risk factors for CAD by mul-
tiple logistic regression analysis. Smoking, hypertension,










Group A vs. C
OR (95% CI)
�
Group B vs. C
M1(+)/NS* 85 (46.2) 67 (36.8) 31 (17.0)
M1(-)/NS 108 (44.2) 94 (38.8) 41 (17.0) 0.16 (0.92) 1.11 (0.53-1.62) 0.98 (0.57-1.64)
M1(+)/S 73 (60.8) 25 (20.8) 22 (18.4) 0.27 (0.87) 0.91 (0.58-1.38) 0.59 (0.34-1.09)
M1(-)/S 90 (61.6) 40 (27.4) 16 (11.0) 8.15 (0.01) 2.01 (1.13-3.69) 1.03 (0.51-2.11)
Table 5. Interaction between GSTM1 genotype and smoking on CAD after adjusting for other risk factors
*, reference; 
� , adjusted for age, sex, hypertension, DM, body mass index, and lipid profile.
Group A, ≥50% in luminal diameter stenosis in coronary angiography; Group B, 20-50% in luminal diameter stenosis in coronary angiography; Group
C, <20% in luminal diameter stenosis in coronary angiography.











Group A vs. C
OR (95% CI)
�
Group B vs. C
T1(+)/NS* 94 (46.1) 77 (37.8) 33 (16.1)
T1(-)/NS 97 (43.8) 79 (36.1) 44 (20.1) 0.21 (0.89) 0.79 (0.43-1.39) 0.59 (0.44-1.09)
T1(+)/S 67 (62.9) 24 (21.9) 16 (15.2) 1.61 (0.44) 0.80 (0.47-1.59) 0.76 (0.40-1.56)
T1(-)/S 98 (60.6) 46 (28.8) 17 (10.6) 7.77 (0.02) 1.89 (1.03-3.13) 1.28 (0.65-2.51)
Table 6. Interaction between GSTT1 genotype and smoking on CAD after adjusting for other risk factors
*, reference; 
� , adjusted for age, sex, hypertension, DM, body mass index, and lipid profile.
Group A, ≥50% in luminal diameter stenosis in coronary angiography; Group B, 20-50% in luminal diameter stenosis in coronary angiography; Group
C, <20% in luminal diameter stenosis in coronary angiography.
GST, glutathione S-transferase; CAD, coronary artery disease; OR, odds ratio; T1(+), GSTT1-positive genotype; T1(-), GSTT1 null genotype; NS, non-
smoker; S, smoker. 








GSTM1-1 39 46.4 28 33.3 17 20.3
GSTM1-0 52 49.1 37 34.9 17 16.0
S 0.21 0.89
GSTM1-1 30 40.5 20 27.0 24 32.5
GSTM1-0 39 43.8 21 23.6 29 32.6
NS 0.89 0.64
GSTT1-1 44 46.8 35 37.2 15 16.0
GSTT1-0 46 48.4 30 31.6 19 20.0
S 1.04 0.59
GSTT1-1 25 37.9 18 27.3 23 34.8
GSTT1-0 44 45.8 22 22.9 30 31.3
NS 0.21 0.89
Both-1 17 43.6 15 38.5 7 17.9
Both-0 24 48.0 17 34.0 9 18.0
S 0.95 0.62
Both-1 10 37.0 7 25.9 10 37.1
Both-0 23 47.9 9 18.8 16 33.3
Table 7. Genotype distributions of GST gene according to the number of affected vessels
GST, glutathione S-transferase; NS, non-smoker; S, smoker; GSTM1-1, GSTM1-positive genotype; GSTM1-0, GSTM1 null genotype; GSTT1-1, GSTT1-
positive genotype; GSTT1-0, GSTT1 null genotype; both-1, GSTM1/T1 both positive genotype; both-0, GSTM1/T1 both null genotype.diabetes, old age more than 50 yr, male, and dyslipidemia
were independent risk factors for CAD. Both GSTM1 and
GSTT1 null genotype in smokers were also independent risk
factors, but GSTM1/T1 null genotype itself was not an inde-
pendent risk factor (Table 9).
DISCUSSION
Cardiovascular diseases and cancer are the main causes of
death in developed countries to which cigarette smoking is
a major contributing factor. Cancer and atherosclerosis share
common risk factors, such as cigarette smoking, physical inac-
tivity, exposure to certain environmental mutagenic agents,
and dietary habits. Autopsy studies have demonstrated high-
er risk for severe atherosclerosis in persons who died from
tobacco-related cancers than those who died from extrane-
ous causes (19). The facts that monoclonal proliferation of
vascular smooth muscle cells in atherosclerosis is similar to
process in carcinogenic progression (20) and that somatic
mutation contributes to the developement of atherosclerosis
(4) suggest that cardiovascular diseases and cancers share com-
mon pathogenic mechanisms.
Epidemiological studies have demonstrated tobacco smoke
is a major cause of both cancer and vascular diseases. How-
ever, the mechanism by which exposure leads to disease is
better understood in the former case. There are many iden-
tified carcinogens in tobacco smoke that induce DNA dam-
age by direct binding to form DNA adducts (21). Unre-
paired DNA damage can result in the induction of somatic
mutations in genes regulating cell growth, thus providing a
mechanism for carcinogenesis.
By contrast, the mechanism by which smoking contributes
the development of vascular diseases is not certain yet. One
possible explanation is that smoking-induced DNA dam-
age causes smooth muscle cell proliferation in the intima of
arteries, thereby contributing to atherothrombotic processes
(14). The hypothesis that DNA damage plays a role in vas-
cular disease has received support from observations in ani-









GSTM1-1 12 14.3 38 45.2 34 40.5
GSTM1-0 23 21.5 36 33.6 48 44.9
S 0.92 0.63
GSTM1-1 9 12.2 25 33.8 40 54.0
GSTM1-0 8 8.9 37 41.1 45 50.0
NS 1.89 0.39
GSTT1-1 17 18.1 32 34.0 45 47.9
GSTT1-0 18 18.8 41 42.7 37 38.5
S 0.08 0.96
GSTT1-1 6 9.1 25 37.9 35 53.0
GSTT1-0 10 10.3 37 38.1 50 51.6
NS 0.73 0.69
Both-1 7 17.9 17 43.6 15 38.5
Both-0 13 25.5 20 39.2 18 35.3
S 1.83 0.40
Both-1 4 14.8 5 18.5 18 66.7
Both-0 5 10.2 16 32.7 28 57.1
Table 8. Genotype distributions of GST gene according to the severity of CAD
GST, glutathione S-transferase; CAD, coronary artery disease; mild, 50-75% of luminal diameter stenosis; moderate, 76-90% of luminal diameter steno-
sis; severe, >90% of luminal diameter stenosis; NS, non-smoker; S, smoker; GSTM1-1, GSTM1-positive genotype; GSTM1-0, GSTM1 null genotype;
GSTT1-1, GSTT1-positive genotype; GSTT1-0, GSTT1 null genotype; both-1, GSTM1/T1 both positive genotype; both-0, GSTM1/T1 both null genotype. 
*, age ≥50 yr.
CAD, coronary artery disease; OR, odds ratio; GST, glutathione S-trans-
ferase; GSTM1/S, GSTM1 null genotype in smoker; GSTT1/S, GSTT1
null genotype in smoker.
OR (95% CI) p value
Hypertension 3.18 (2.01-4.78) <0.005
Diabetes 2.91 (1.81-4.61) <0.005
Age* 2.89 (1.89-4.44) <0.005
Smoking 2.22 (1.12-3.56) <0.05
Sex (male) 2.37 (1.20-3.71) <0.05
Dyslipidemia 2.18 (1.42-3.34) <0.001
GSTM1/S 2.07 (1.06-4.07) <0.05
GSTT1/S 2.00 (1.05-3.84) <0.05
GSTM1 1.31 (0.79-2.16) 0.28
GSTT1 1.14 (0.79-1.65) 0.48
Table 9. Independent risk factors of CADmal models and humans. In experimental animals, chemi-
cals in tobacco smoke (e.g., benzo(a)pyrene, 1,3-butadiene)
and environmental tobacco smoke have been reported to
induce and stimulate atherosclerotic plaque formation (11).
In addition, in both humans and animals, tobacco carcino-
gens induce DNA adducts in cells of the vasculature at high
levels, and aromatic DNA adducts are present in smooth
muscle cells of human atherosclerotic lesion of the abdomi-
nal aorta and in heart tissue (22).
GST is a family of enzymes that detoxify reactive electro-
philes, particularly present in tobacco smoke, reactive oxy-
gen species, and known or suspected carcinogenic compounds
(7). Modulation of DNA damage and mutation caused by
polymorphisms in detoxification enzymes, including the
GST, is a well-established risk factor for tobacco-related car-
cinogenesis and a similar change in cellular damage may be
involved in the risk of vascular disease associated with tobac-
co smoking (23). Also the binding of xenotoxic chemicals
to DNA is modulated by detoxification enzymes such as
GST. Of four classes of GST isoenzymes, null genotypes of
GSTM1 which belongs to the  class and of GSTT1 which
is in the  class are associated with increased risk of smoking-
related cancer (10, 11, 13). However, association of GSTM1/
T1 gene polymorphism with smoking-related CAD is revealed
in few studies and the results of these studies are different
(7, 17, 24).
In this study, we tested whether specific genotypes of
GSTM1 or GSTT1 may affect susceptibility to smoking-
related CAD. The null genotype of GSTM1 and GSTT1 in
smokers were associated with an increase in the risk of CAD
(OR, 2.07, CI, 1.06-4.07, p=0.03; OR, 2.0, CI, 1.05-3.84,
p=0.03), respectively. The effects of GSTM1/GSTT1 geno-
type on CAD were augmented when both GSTM1 and GS-
TT1 genotype were null type (OR, 2.76, CI, 1.17-6.52,
p=0.04). However, smokers with GSTM1/GSTT1-positive
genotype had no increased risk for CAD as compared with
non-smokers (OR, 1.21, CI, 0.64-2.27; OR, 1.44, CI, 0.74-
2.84, respectively). In non-smokers, there was no difference
in risk for CAD in relation to GSTM1/GSTT1 genotype
(OR, 0.96, CI, 0.56-1.66; OR, 0.77, CI, 0.45-1.31, respec-
tively). These facts suggest that there may be different dis-
ease susceptibility to CAD according to the GSTM1/GSTT1
genotypes in smokers.
As mentioned above, there are still some controversies about
the relationship between GST polymorphism and CAD in
smokers. An epidemiological study showed that smokers with
GSTM1 null genotype have a consistently higher prevalence
of CAD (7). De Waart and colleagues reported that the 2-yr
progression of common carotid intima media thickness was
clearly more increased in smokers with the GSTM1 null
genotype than in smokers with the GSTM1-positive geno-
type (25). Recent data also suggest that the GSTM1 null
genotype predisposes subjects to severe CAD (26). Our study
showed similar results to those previously reported. By con-
trast, another study reported a significantly decreased risk
for acute myocardial infarction in smoking patients with
GSTM1 null genotype, but only in those having a previous
history of the same disease (17).
Meanwhile, previous studies showed the more diverse
results about the effects of GSTT1 gene polymorphism on
smoking-related CAD. A recent study and our study found
that smokers with GSTT1 null genotype had increased risk
for CAD (24), but other studies revealed that GSTT1 posi-
tive genotype was associated with increased risk for CAD
and peripheral artery diseases (7). A possible explanation for
these conflicting results is that GSTT1 protein activates some
chemicals present in cigarette smoke in more toxic forms
and increase the risk of atherosclerosis (7). Indeed, although
mammalian GST  behaves as a scavenger towards electro-
philes such as epoxides, it acts also as metabolic activator,
producing intermediates potentially dangerous for DNA
and cells (27). However, cytogenetic studies have shown that
blood cultures from individuals with GSTT1 null and GSTM1
null genotypes have increased in vitro sensitivity to various
genotoxins resulting in an increased level of chromosomal
and oxidative DNA damage in lymphocytes (28). And lev-
els of adducts to DNA in smooth muscle cells from atheroscle-
rotic lesions are consistently increased in individuals having
the GSTM1 null genotype (22). Consequently, genetic poly-
morphisms that affect xenobiotic metabolism or cellular
response to DNA damage by modulating individual sensi-
tivity to genotoxins may be important in modulating sus-
ceptibility to both cancer and atherosclerosis. In particular,
the polymorphic genes of GST family of enzymes, which are
involved in the detoxification of many compounds in cigarette
smoke, may be relevant to the susceptibility to smoking-relat-
ed diseases.
The effect of cigarette smoking on atherosclerosis involves
many metabolic and biological processes, such as endothe-
lial injury, oxidation of low-density lipoprotein and changes
in the hemostatic system (29). In addition, some of the adverse
effects of smoking may result from DNA damage by geno-
toxic and carcinogenic agents including polycyclic aromatic
hydrocarbons, n-nitrosamines, and reactive oxygen species
in cigarette smoke. 
Our data may provide additional information to the under-
standing of smoking-related cardiovascular risk. Although
there are several mechanisms of smoking-related CAD, it is
thought to be important that deleted polymorphisms in the
GST genes may influence the susceptibility to smoking-in-
duced CAD by modulating the detoxification of genotoxic
atherogens.
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